Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinoma.
A. Prosz, H. Duan, V. Tisza, P. Sahgal, S. Topka, G. T.Klus, J. Borscok, Z. Sztupinszki, T. Hanlon, M. Diossy, L. Vizkeleti, D. R. Stormoen, I. Csabai, H. Pappot, J. Vijai, , Z. Szallasi
This paper identifies NER deficiency as a targetable vulnerability in ccRCC, showing that 10% of patients may respond to irofulven based on mutational signatures and PTGR1 expression.
bioRxiv · Feb 7, 2023Cancer Biology